NCT02145637View on ClinicalTrials.gov

Phase I Study of the Combination of Afatinib and Ruxolitinib in Patients With Treatment-refractory Non-Small Cell Lung Cancer (NSCLC)

PHASE1CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

May 7, 2015

Primary Completion Date

November 9, 2017

Study Completion Date

November 9, 2017

Conditions
NSCLC
Interventions
DRUG

Afatinib plus Ruxolitinib combination therapy

All Listed Sponsors
lead

Yonsei University

OTHER

NCT02145637 - Phase I Study of the Combination of Afatinib and Ruxolitinib in Patients With Treatment-refractory Non-Small Cell Lung Cancer (NSCLC) | Biotech Hunter | Biotech Hunter